Osimertinib opens the door for patients with EGFR-mutated advanced non-small cell lung cancer and a poor performance status: comment on the OPEN/TORG2040 trial
Fields of Study & Subjects
Lung Cancer Treatments and Mutations
Lung Cancer Diagnosis and Treatment
HER2/EGFR in Cancer Research
Publication details
- Journal / source
- Translational Lung Cancer Research
- Volume
- 15
- Issue
- 2
- Pages
- 45–45
- Publication date
- 1 February 2026
- Language
- EN